NOWDiagnostics is structured around development and manufacture of diagnostic tests requiring a single drop of blood opening up the option of very rapid delvery of results: minutes not hours/days and potentially reinventing how diagnostic lab test could now being done, The firm's at-home and in-clinic diagnostic tests simplifies the process of testing for common ailments such as food intolerance and allergies, STDs and respiratory/chronic illnesses, enabling patients and caregivers to make intelligent healthcare choices. Headquartered in Arkansas but having faciliites In Toronto Canada and Rome, Italy, in this modern pandemic world, the most dramatic impact could be the development and widespread use of the Corvid19 diagnostic. In December 2020 the firm's ADEXUSDx® COVID-19 Antibody Test was Filed for Point of Care Emergency Use Authorization and received Conformité Européene (CE) mark approval. In late August 2020 it was announced that BARDA - Biomedical Advanced Research and Development Authority arm of the U.S. Department of Health and Human Services - had funded NOWDiagnostics to develop a serological test for SARS-CoV-2 antibodies that can be used across a variety of health care settingsfrom clinics to hospital emergency roomsand ultimately by consumers for at-home use. The COVID-19 rapid antibody test, using NOWDiagnostics self-contained ADEXUSDx® platform, is reported as requiring no additional materials (reagents and buffers), equipment, processing, or refrigeration. No matter where it is conducted, the ADEXUSDx® COVID-19 Test is designed to deliver lab-quality results in 15 minutes detecting the presence of SARS-CoV-2 antibodies in individuals who may have been exposed to the virus. This can include those who have been recently or previously infected with COVID-19, regardless of whether they presented with severe, moderate, mild or no symptoms.
